At ACR Convergence 2023, experts addressed important topics in gout research, including treating and preventing gout flares, lowering urate levels and managing comorbidities, as well as racial inequities in gout treatment, disease burden and outcomes.
Gout Resource Center
Earlier this year, the ACR released a new guideline for the management of gout, leaving some rheumatologists unsure what to recommend to their patients. Clearing up the confusion is one aim of the session, Evidence-Based Guidance for Optimizing Gout Management. Learn what the experts recommend and explore our coverage of additional gout information presented at ACR Convergence 2020, plus our collection of research reviews, case reports and clinical articles on advances in the diagnosis and management of gout.
VIEW
Old Disease, New Tricks: A Novel Approach to Understanding Gout
SAN DIEGO—Gout has sometimes been called the disease of kings, not only because of the fact that purine-rich foods were long affordable only to wealthier individuals, but also because the disease has been around since the monarchies that existed centuries ago. However, with groundbreaking research leading to a better understanding of gout, we can now…
How to Reduce Gout Flares
SAN DIEGO—If patients with gout keep their serum urate (SU) levels very low with urate-lowering therapy (ULT), they have fewer flares, according to a research abstract presented at ACR Convergence 2023.
FDA Approves Canakinumab to Treat Gout Flares
Canakinumab has received FDA approval for the treatment of patients with acute gout flares.
3 AC&R Study Summaries: Fractures in Patients with SSc, Clinical Response in JIA, & TV & the Public Perception of Gout
Fractures in Patients with SSc By Zsuzsanna McMahan, MD, MHS Why was this study done? To minimize disability due to systemic sclerosis (SSc), it’s important to prevent and manage complications. Many SSc complications and related medications may increase the risk for osteoporosis and fracture. We sought to identify modifiable risk factors for fracture in patients…
Pegloticase Plus Methotrexate Effective for Uncontrolled Gout
The 12-month results of the MIRROR study show pegloticase co-administered with methotrexate is beneficial for patients with uncontrolled gout.
Treat to Target Lowers the Risk of Fracture in Patients with Gout
Using data from the U.K.’s Health Improvement Network, a primary care database, Wei et al. examined whether urate-lowering therapy (ULT) in a treat-to-target approach for patients with gout reduces the risk of fracture.
Tigulixostat Promising for Patients with Gout & Hyperuricemia
In a dose-finding, clinical trial, Terkeltaub et al. examined the safety and efficacy of tigulixostat, a nonpurine xanthine oxidase inhibitor, for lowering the serum urate levels of patients with gout and hyperuricemia.
Point-of-Care Uric Acid Testing
In June 2022, I listened to several presentations on gout at EULAR’s European Congress of Rheumatology. Most began with data confirming a sad truth that we, as rheumatology providers, are all aware of: too many patients are taking subtherapeutic doses of urate-lowering therapy (ULT).1,2 Recommendations from the American College of Physicians in 2017 advocated for…
3 AC&R Study Summaries: Treat to Target in Gout, Response to Biologics in Patients with JIA, & Rehabilitation Dose in Adults with RA
Treat to Target in Gout Monitoring & achievement of target serum urate levels By Jing Li & Gabriela Schmajuk, MD, MS Why was this study done? The ACR’s 2020 guideline for the management of gout recommends using a treat-to-target (T2T) approach to lower serum urate (SU). Using the ACR’s RISE registry, we examined the use…
- 1
- 2
- 3
- …
- 20
- Next Page »